Skip to main content
Clinical Trials/NCT05871762
NCT05871762
Recruiting
Not Applicable

Choice of the Optimal Treatment Strategies for Mid-low REctal Cancer-a National Multi-center, Prospective, Real World Study

Peking Union Medical College Hospital1 site in 1 country3,705 target enrollmentJune 4, 2023

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Rectal Neoplasms
Sponsor
Peking Union Medical College Hospital
Enrollment
3705
Locations
1
Primary Endpoint
3-year OS
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

The purpose of this study is to compare the efficacy, prognosis, health economics of different treatment modalities of mid-low rectal cancer in different centers in China, and to conduct cost utility analysis (CUA) on the treatment process of rectal cancer to explore the best treatment modality that meets the actual need of medical units in each region and at each level. The investigators hope to provide evidence-based medical suggestions for medical quality control of rectal cancer and revision of clinical guidelines, and provides a source of decision making for medical management and medical insurance.

Registry
clinicaltrials.gov
Start Date
June 4, 2023
End Date
May 17, 2027
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • pathologically confirmed rectal adenocarcinoma
  • located within 12cm below the anal verge

Exclusion Criteria

  • diagnosed with distant metastasis
  • multiple primary colorectal cancers
  • history of previous malignant tumors
  • Pregnant or lactating women

Outcomes

Primary Outcomes

3-year OS

Time Frame: 3 years

3-year overall survival

Secondary Outcomes

  • 3-year DFS(3 years)
  • 3-year LR(3 years)
  • adjuvant therapy rate(at the time point of 3-year follow up)
  • EUS/MRI assessment rate(at the time point of surgery of the primary lesion)
  • 3-year distant metastasis rate(3 years)
  • neoadjuvant therapy rate(at the time point of surgery of the primary lesion)
  • R0 resection rate(at the time point of surgery of the primary lesion)
  • CCR(immediately after the completion of neoadjuvant therapy assessment)
  • pCR(immediately after the completion of surgery)
  • 30-day mortality(30 days after the surgery)

Study Sites (1)

Loading locations...

Similar Trials